secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)
CIK:        0001100682
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001100682-26-000036
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Charles River Q1 GAAP EPS $(0.30), non-GAAP $2.06; reaffirms FY2026 guidance
----------------------------------------------------------------------------

- Q1 revenue $995.8M (+1.2% reported, -1.5% organic); GAAP loss $(0.30) vs $0.50 prior year.
- Non-GAAP EPS $2.06, down 12% YoY; non-GAAP operating margin 16.3% vs 19.1%.
- Completed divestiture of CDMO and Cell Solutions to GI Partners on May 6, 2026; European sites expected in May.
- Repurchased $200M of stock in Q1; $800M remaining under $1B authorization.
- Reaffirmed FY2026 organic revenue (-1.5% to -0.5%) and non-GAAP EPS $10.80-$11.30; lowered reported revenue outlook ~50bps due to FX.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1100682/000110068226000036/0001100682-26-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1100682/000110068226000036/crl-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001100682-26-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer